Jasper Therapeutics appoints COO Jeet Mahal as CEO; Ron Martell steps down, Thomas Wiggans named Executive Chair

Jasper Therapeutics, Inc.

Effective Jan 5, 2026, Jeet Mahal becomes CEO and President; he also joins the Board as Class III director.
Outgoing CEO Ron Martell's departure is without cause; he receives 18 months base salary plus COBRA for up to 18 months.
Thomas Wiggans, current Board Chair, appointed Executive Chair effective Jan 5, 2026.
Mahal's annual salary increased to $600,000 with eligibility for performance bonus up to 50% of base salary.
Company to host investor webinar on Jan 8, 2026 to present updated data from BEACON study and open-label extension in CSU/CIndU.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.